• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • COVID-19
  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • Artificial Intelligence
    • Blockchain
    • Mobile Health
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Tempus

University of California Davis, Tempus Partner on Personalized Cancer Initiative

by Jasmine Pennic 08/31/2017 Leave a Comment

University of Michigan, Tempus Partner on Personalized Cancer Medicine for Breast Cancer Patients

University of California Davis Comprehensive Cancer Center is collaborating with technology company Tempus on a precision medicine partnership. The new collaboration will focus on advancing clinical care with Next Generation Sequencing analysis for patients diagnosed with hematological malignancies and pancreatic cancer.Collaboration DetailsTempus will perform molecular sequencing and analysis for a group of patients at UC Davis Comprehensive Cancer Center. Utilizing machine learning and
Read More

University of California San Diego, Tempus Partner on Personalized Medicine Initiative

by HITC Staff 07/06/2017 Leave a Comment

University of Michigan, Tempus Partner on Personalized Cancer Medicine for Breast Cancer Patients

Tempus, a technology company focused on helping doctors personalize cancer care by collecting, sorting and analyzing clinical and molecular data, will provide Moores Cancer Center at UC San Diego Health with molecular sequencing, analysis and decision support tools to enable further research on immune checkpoint inhibitors across cancer types. Tempus provides molecular sequencing and clinical analytic solutions to top academic centers, hospital systems, associations, and healthcare
Read More

University of Chicago Medicine, Tempus Partner on Personalized Pancreatic Cancer Project

by Fred Pennic 06/22/2017 Leave a Comment

University of Chicago Medicine, Tempus Partner on Personalized Pancreatic Cancer Project

Pancreatic cancer is the third leading cause of cancer-related death in the United States. It has a five-year survival rate of just nine percent. Lack of effective treatments and early detection methods contribute to this grim prognosis. Personalized approaches to match a patient’s genomic information to therapies have led to improvements in treatment of other cancer types. None of the genetic mutations commonly seen in pancreatic cancer, however, have “druggable” targets.That’s why the
Read More

University of Michigan, Tempus Partner on Personalized Breast Cancer Medicine Initiative

by Fred Pennic 06/12/2017 Leave a Comment

University of Michigan, Tempus Partner on Personalized Cancer Medicine for Breast Cancer Patients

Breast cancer is the most common non-skin cancer and the second leading cause of cancer-related death in women. In 2017, it is estimated that more than 250,000 U.S. women will be diagnosed with new cases of invasive breast cancer. That’s why the University of Michigan Comprehensive Cancer Center has partnered with Tempus on a personalized cancer medicine initiative aimed providing most effective care for individuals diagnosed with breast cancer.As part of the initiative, Tempus will use
Read More

Northwestern, Tempus Expand Partnership to Accelerate Personalizing Care for Cancer Patients

by Fred Pennic 05/11/2017 Leave a Comment

Northwestern, Tempus Expand Partnership to Accelerate Personalizing Care for Cancer Patients

The Robert H. Lurie Comprehensive Cancer Center of Northwestern University is expanding its partnership with Tempus aimed at personalizing care for cancer patients. Tempus provides molecular sequencing and clinical analytic solutions for top academic centers, hospital systems, associations, and healthcare providers.As part of the expanded collaboration, Tempus will provide molecular sequencing and analysis for patient derived xenograft (PDX) models and patient derived organoid models, which will
Read More

Penn Medicine’s Abramson Cancer Center Launches Initiative to Improve & Personalize BRCA Mutations

by HITC Staff 04/28/2017 Leave a Comment

Penn Medicine's Abramson Cancer Center Launches Initiative to Improve & Personalize BRCA Mutations

Cancer experts at the Basser Center for BRCA in the Abramson Cancer Center of the University of Pennsylvania have announced a new collaboration with Tempus to improve and personalize treatment for patients with heritable BRCA mutations. Tempus, a technology company focused on helping doctors personalize cancer treatment will analyze the molecular and clinical data of patients who were treated at the Basser Center and harbor a BRCA mutation using machine learning and advanced
Read More

  • Previous Page
  • Go to page 1
  • Go to page 2
  • Go to page 3

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Most Popular

Northwell Health Extends Contract with Allscripts Sunrise Platform Through 2027

Northwell to Deploy Epic Enterprise EHR Platform Across System

Sanofi Cuts Price of Lantus Insulin by 78% & Caps Out of Pocket Costs at $35 for All Patients

Sanofi Cuts Price of Lantus Insulin by 78% & Caps Out of Pocket Costs at $35 for All Patients

Pfizer Acquires Seagen for $43B to Tackle Cancer

Pfizer Acquires Seagen for $43B to Tackle Cancer

5 Key Trends Driving Purchasing Decisions in Healthcare IT

5 Key Trends Driving Purchasing Decisions in Healthcare IT

Sanofi to Acquire Diabetes Therapy Maker Provention Bio for $2.9B

Sanofi to Acquire Diabetes Therapy Maker Provention Bio for $2.9B

Dr. Arti Masturzo

Q/A: Dr. Masturzo Talks Addressing Food Insecurity with Patients

Transcarent Acquires 98point6 AI-Powered Virtual Care Platform and Care Business

Transcarent Acquires 98point6 AI-Powered Virtual Care Platform and Care Business

Eli Lilly Cuts Insulin Prices by 70%, Caps Patient Costs at $35 Per Month

Eli Lilly Cuts Insulin Prices by 70%, Caps Patient Costs at $35 Per Month

Q/A: Oatmeal Health Co-Founder Talks AI-Enabled Cancer Screening for the Underserved

Q/A: Oatmeal Health Co-Founder Talks AI-Enabled Cancer Screening for the Underserved

GE HealthCare to Acquire Caption Health

GE HealthCare to Acquire Caption Health to Expand AI-Guided Ultrasounds

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • 2023 Editorial Calendar
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2023. HIT Consultant Media. All Rights Reserved. Privacy Policy |